Dyne Therapeutics, Inc
Follow $DYN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $DYN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is DYN moving today?
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
DYN overview
Related filings and maps
Congress activity in DYN
No receipt-qualified Congressional disclosure is present for DYN in the cached public ledger.
DYN contract awards, year to date.
Public federal awards linked to this ticker.
DYN lobbying filings, year to date.
Registered lobbying filings matched to Dyne Therapeutics, Inc.